In the early 1980s, LHRH agonists were introduced [3] in the endocrinological treatment of advanced prostate cancer, and the oncological outcomes of surgical castration by bilateral orchidectomy and medical castration by LHRH agonists are now generally regarded as the similar. Here, GNRH1 is linked to prostate cancer.